Loading...
XASE
RVP
Market cap24mUSD
Dec 05, Last price  
0.82USD
1D
0.61%
1Q
3.51%
Jan 2017
-11.83%
IPO
-92.00%
Name

Retractable Technologies Inc

Chart & Performance

D1W1MN
XASE:RVP chart
P/E
P/S
0.74
EPS
Div Yield, %
Shrs. gr., 5y
-1.73%
Rev. gr., 5y
-4.59%
Revenues
33m
-24.19%
24,235,01625,324,51926,289,72027,899,31838,981,83736,219,56232,102,29633,644,50330,785,12734,520,63029,552,20029,826,63634,493,83833,274,70241,797,17981,862,453188,382,45494,818,93843,596,92633,049,533
Net income
-12m
L+69.54%
-1,238,323-3,869,484-6,948,104-9,643,580-9,422,3002,400,6941,418,482-4,132,892-6,213,852-2,354,6054,314,318-3,694,907-3,736,038-1,339,9433,148,23424,223,01356,064,2415,078,557-7,011,036-11,886,524
CFO
-12m
L
-2,234,899-3,354,031-4,216,671-5,923,242-12,299,7318,730,6725,513,773158,3372,933,569-3,867,822-3,252,157-794,912-2,922,636-1,195,4952,194,63818,997,02932,793,49916,768,1282,766,848-11,557,036

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
IPO date
May 04, 2001
Employees
190
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT